Ken Griffin Atreca, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.88 - $1.22 $6,184 - $8,574	-7,028 Reduced 94.11%	440 $0
Q1 2023 May 15, 2023	SELL	$0.91 - $1.82 $10,778 - $21,557	-11,845 Reduced 61.33%	7,468 $8,000
Q4 2022 Feb 14, 2023	SELL	$0.78 - $1.68 $20,443 - $44,032	-26,210 Reduced 57.58%	19,313 $15,000
Q3 2022 Nov 14, 2022	SELL	$1.59 - $2.74 $132,839 - $228,918	-83,547 Reduced 64.73%	45,523 $71,000
Q2 2022 Aug 15, 2022	BUY	$1.56 - $3.25 $50,392 - $104,984	32,303 Added 33.38%	129,070 $231,000
Q1 2022 May 16, 2022	SELL	$1.61 - $5.2 $51,784 - $167,252	-32,164 Reduced 24.95%	96,767 $307,000
Q4 2021 Feb 14, 2022	SELL	$2.87 - $6.29 $7,364 - $16,140	-2,566 Reduced 1.95%	128,931 $390,000
Q3 2021 Nov 15, 2021	SELL	$4.91 - $9.07 $2.44 Million - $4.5 Million	-495,991 Reduced 79.04%	131,497 $819,000
Q2 2021 Aug 16, 2021	BUY	$7.82 - $13.8 $2.04 Million - $3.6 Million	260,780 Added 71.11%	627,488 $5.35 Million
Q1 2021 May 17, 2021	SELL	$13.0 - $19.34 $3.17 Million - $4.72 Million	-243,837 Reduced 39.94%	366,708 $5.62 Million
Q4 2020 Feb 16, 2021	BUY	$13.03 - $17.09 $436,244 - $572,173	33,480 Added 5.8%	610,545 $9.86 Million
Q3 2020 Nov 16, 2020	BUY	$12.67 - $23.19 $5.76 Million - $10.5 Million	454,864 Added 372.23%	577,065 $8.06 Million
Q2 2020 Aug 14, 2020	SELL	$12.52 - $23.45 $1.87 Million - $3.5 Million	-149,179 Reduced 54.97%	122,201 $2.6 Million
Q1 2020 May 15, 2020	BUY	$11.4 - $27.28 $1.14 Million - $2.74 Million	100,308 Added 58.63%	271,380 $4.49 Million
Q4 2019 Feb 14, 2020	BUY	$9.68 - $18.67 $1.08 Million - $2.08 Million	111,507 Added 187.2%	171,072 $2.65 Million
Q2 2019 Aug 14, 2019	BUY	$17.07 - $18.84 $1.02 Million - $1.12 Million	59,565 New	59,565 $1.12 Million

Others Institutions Holding BCEL

# of Institutions

Shares Held

30.6K

Call Options Held

Put Options Held

View Full List

About Atreca, Inc.

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

More about BCEL

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account